Related Experiment Video
Updated: May 23, 2025

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
Published on: February 16, 2011
Suboptimal practices in harm reporting: a meta-epidemiological study on metrics, recurrence, and exposure duration in
Qiao Huang1, Wen Wang2, Liang Zheng3
1Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China; Department of Evidence-Based Medicine and Clinical Epidemiology, Second School of Clinical Medicine, Wuhan University, Wuhan, China.
Objectives:
The Consolidated Standards of Reporting Trials (CONSORT) Harms 2022 statement emphasizes the necessity for clinical trials to clearly address the duration of follow-up and recurrence of adverse events in safety analysis, highlighting the importance of using appropriate measures for a comprehensive risk assessment. This study aimed to provide guidance on metrics in harm profile reporting and evaluating current practices in clinical trials against the CONSORT Harms 2022 recommendations.
Study Design And Setting:
We have summarized characteristics of four reporting metrics-cumulative incidence rate, cumulative event rate, exposure-adjusted incidence rate (EAIR), and exposure-adjusted event rate (EAER). To evaluate the current reporting patterns, we conducted a meta-epidemiological study of 116 clinical trials published in four top-tier medical journals from September 1, 2023, to December 31, 2023.
Results:
The cumulative incidence rate was the most frequently used metric (81.03%), followed by a simple count (16.38%), EAER (3.45%), EAIR (2.59%), and cumulative event rate (0.86%). A total of 105 trials (91.38%) used a single measure and 10 trials (8.62%) incorporated 2 different measures. Only 14 trials (12.07%) gave explicit evidence for the reporting of recurrent adverse events and six trials (5.17%) explicitly stated their rationale for not considering recurrence. Adjustments for exposure duration were notably absent in trials with unequal dropout rates and exposure times.
Conclusion:
Recurrence of adverse events and varied exposure duration were inadequately addressed in current practices. Future trials should adopt transparent and sophisticated metrics in reporting them to capture a multidimensional and reliable representation of harm profiles.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders
Blinding
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Ethics in Research

